Articles tagged "Immunosuppression"

2016 American Transplant Congress
Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
P. Ueno,¹ H. Tedesco,¹ A. Brigido,¹ C. Felipe,¹ P. Hannun,¹ M. Cristelli,¹ W. Aguiar,² J. Medina-Pestana.¹
¹Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil; ²Urology Division, Hospital do Rim, Sao Paulo, Brazil.
Background: Regimens with de novo everolimus (EVR) are associated with a concentration-dependent incidence of wound healing adverse events (WHAE), but mycophenolate use also is related…
2016 American Transplant Congress
Post-Trial Experience with Belatacept: A Large Single Center Experience.
A. Adams, C. Garrett, J. Goldstein, R. Zhang, A. Guasch, S. Pastan, R. Patzer, A. Kirk, T. Pearson, C. Larsen.
Emory Transplant Center, Atlanta, GA.
Evaluation of belatacept in clinical trials revealed significant improvements in renal function and cardiovascular risk leading to superior survival. Despite these proven benefits higher rates…
2016 American Transplant Congress
Conversion to Once-Daily Tacrolimus in Stable Pediatric Liver Transplantation Recipients.
N. Lee, S. Lee, C.-W. Cho, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, S.-K. Lee.
Department of Surgery Organ Transplant Center, Samsung Medical Center, Seoul, Republic of Korea.
Purpose: Pediatric patients are known to have lower compliance than adult patients. Once-daily formulation of tacrolimus may increase compliance in pediatric liver transplant recipients. The…
2016 American Transplant Congress
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.
M. Burke,¹ L. Nahum,⁴ N. Isbel,¹ R. Carroll,³ H. Soyer,¹ R. Francis,¹ J. Bridge,¹ C. Staatz,² J. Wells.¹
¹Translational Research Institute, Brisbane, Australia; ²University of Queensland, Brisbane, Australia; ³Royal Adelaide Hospital, Adelaide, Australia; ⁴Ben Gurion University of the Negev, Beersheba, Israel.
BackgroundKidney transplant recipients (KTR) receiving sirolimus accrue fewer skin cancers than KTR receiving calcineurin inhibitor (CNI) based immunosuppression, potentially due to effects of sirolimus and…
2016 American Transplant Congress
Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.
A. Mihali,¹ E. Sula Karreci,¹ A. Kurdi,³ L. Riella,¹ Y. Kawano,³ H. Fan,² P. Singh,² I. Ghobrial,³ C. Nathan,² G. Lin,² J. Azzi.¹
¹Transplantation Research Center, Harvard Medical School, Boston; ²Department of Microbiology and Immunology, Weill Cornell Medicine, NY; ³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
Antibody mediated rejection (AMR) is one of the most important barriers to improving long-term transplant outcomes. Traditional therapies for AMR do not deplete the source…
2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
M. Willicombe, D. Goodall, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…
2016 American Transplant Congress
Graft Survival of Steroid-Avoidance Protocols in Pediatric Kidney Transplantation[mdash]A Propensity Score Analysis.
E. Nehus,¹ Y. Wang,² B. Lu,³ C. Liu,² M. Macaluso,² M.-O. Kim.²
¹Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ²Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ³Division of Biostatistics, The Ohio State University, Columbus, OH.
Purpose: This study investigated whether steroid avoidance-protocols adversely influence allograft survival among pediatric kidney transplant recipients at high levels of immunologic risk.Methods: A retrospective cohort…
2016 American Transplant Congress
Peritransplant Costimulation Blockade Combined with a Short-Course of Rapamycin Prevents Rejection of Vascularized Composite Allografts.
B. Oh, G. Furtmüller, M. Fryer, P. Akre, D. Cooney, W. Lee, G. Raimondi, G. Brandacher.
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…
2016 American Transplant Congress
Heat Shock Protein 90 Inhibitor 17DMAG Is a Potential New Therapeutic Agent Against Acute Allograft Rejection.
T. Maehana,¹ T. Tanaka,¹ H. Kitamura,² N. Masumori.¹
¹Urology, Sapporo Medical University School of Medicine, Sapporo, Japan; ²Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan.
Purpose: We have previously demonstrated that Heat shock protein 90 (HSP90) plays a role in the development of acute rejection (AR) in organ transplantation. To…
2016 American Transplant Congress
Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.
A. Santeusanio, A. Owusu-Obeng, J. Jeff.
Mount Sinai Hospital, New York.
Objective: to assess tacrolimus dosing requirements based upon ethnicity in order to help guide future decisions regarding dosage initiation and titration among Hispanic and African…